High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Tools
Tools
Tools
Stupp, R., Tonn, J. C., Brada, M., Pentheroudakis, G., ESMO Guidelines Working Group, [Group Author]
(2010)
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
ANNALS OF ONCOLOGY, 21 (Supple).
v190-v193.
ISSN 0923-7534
Full text not available from this repository.
A copy of the full text may be available at: http://annonc.oxfordjournals.org/content/21/suppl_...
| Item Type: | Article |
|---|---|
| Authors (ICR Faculty only): | Brada, Michael |
| All Authors: | Stupp, R., Tonn, J. C., Brada, M., Pentheroudakis, G., ESMO Guidelines Working Group, [Group Author] |
| Uncontrolled Keywords: | PHASE-III TRIAL; MGMT PROMOTER METHYLATION; EUROPEAN-ORGANIZATION; GLIOBLASTOMA-MULTIFORME; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; RADIATION-THERAPY; TUMOR; RADIOTHERAPY; CHEMOTHERAPY |
| Funding Acknowledgement: | Schering-Plough ; Merck KgaA ; Bristol-Myers-Squibb ; Roche (Avastin) ; OncoMethylome Sciences ; Essex (Temozolomide) ; Merck Serono (Cilengitide) |
| Funding Text: | Dr Stupp has reported that he has been a consultant and has received honoraria from Schering-Plough, Merck KgaA, Bristol-Myers-Squibb, Roche and OncoMethylome Sciences. He has also reported that he holds stock in Pfizer; Professor Tonn has reported that he has received travel grants and speakers' honoraria from Essex (Temozolomide), Roche (Avastin) and Merck Serono (Cilengitide); Professor Brada and Dr Pentheroudakis have reported no conflicts of interest. |
| Research teams: | Closed research groups > Clinical Academic Radiotherapy (Brada) Clinical Units > Neuro-oncology Unit |
| Depositing User: | Users 10 not found. |
| Date Deposited: | 09 Jul 2010 12:10 |
| Last Modified: | 21 Sep 2011 12:33 |
| URI: | http://publications.icr.ac.uk/id/eprint/9729 |
Actions (login required)
 |
View Item |
